Related Experiment Videos
Pharmacotoxic myocardial disease: an endomyocardial study
Heart and Vessels. Supplement
|January 1, 1985
Summary
Drug cardiotoxicity is a growing concern, potentially causing myocarditis or cardiomyopathy. Early diagnosis via endomyocardial biopsy is crucial for managing these adverse drug effects.
Area of Science:
- Cardiology
- Pharmacology
- Toxicology
Background:
- Drug-induced toxic changes in the myocardium are an increasing clinical problem.
- Adverse drug reactions can manifest as acute or cumulative effects on heart morphology.
- These effects include myocarditis, cardiomyopathy, and restrictive heart disease.
Purpose of the Study:
- To review the mechanisms and manifestations of drug-induced heart disease.
- To categorize drugs based on their cardiotoxic effects.
- To highlight the importance of diagnostic tools like endomyocardial biopsy.
Main Methods:
- Review of literature on drug-induced cardiotoxicity.
- Classification of cardiotoxic drugs based on observed cardiac pathology.
- Discussion of diagnostic approaches, including endomyocardial biopsy.
Main Results:
- Drug-induced myocarditis can be toxic (e.g., cyclophosphamide) or hypersensitivity-related (e.g., thiazide diuretics).
- Cardiomyopathy with ventricular dilatation is associated with drugs like anthracyclines (e.g., adriamycin).
- Fibrous endocarditis can result from drugs such as methysergide.
Conclusions:
- Drug cardiotoxicity presents diverse pathologies, including myocyte necrosis, fibrosis, and chamber dilatation.
- The increasing development of new drugs necessitates ongoing vigilance for cardiotoxicity.
- Endomyocardial biopsy aids in documenting drug-induced heart disease and exploring therapeutic strategies.